论文部分内容阅读
盘尾丝虫病是一种迄今未能治愈的重要致盲病。伊维菌素是一种安全、有效、广谱的抗寄生虫药物。当它用于治疗盘尾丝虫病患者时,可降低病人传播盘尾丝虫病的能力。本实验用伊维菌素进行盘尾丝虫病的群体治疗,试图证实伊维菌素作群体治疗可以减少新感染的发生率。 1987年9月～1989年11月在利比里亚的一个森林区盘尾丝虫病流行区,对居住在橡胶种植园的约14000人每年进行伊维菌素群体治疗。12岁以上的人均给予伊维菌素。儿童经皮肤小片活检及偏正光图像证实
Onchocerciasis is an important blinding disease that has so far failed to heal. Ivermectin is a safe, effective, broad-spectrum anti-parasitic drug. When used to treat onchocerciasis, it reduces the patient’s ability to transmit onchocerciasis. This experiment with ivermectin onchocerciasis group treatment, trying to confirm that ivermectin for group therapy can reduce the incidence of new infections. From September 1987 to November 1989 in an area of forest-borne filariasis in Liberia, about 14,000 people living in rubber plantations were treated with ivermectin annually. Ivermectin is given to people over the age of 12. Transdermal biopsies and polarized images of children confirmed